CLDN8 Antibody

What is CLDN8 and what are its primary biological functions?

CLDN8 is a protein that functions as a critical component of tight junction strands, which are integral to maintaining cell-to-cell adhesion . It is primarily expressed at tight junction structures located in distal aldosterone-sensitive nephrons and the posterior thin descending limb segments of long-looped nephrons in the mammalian kidney . CLDN8 plays a crucial role in regulating paracellular ion permeability, particularly chloride ions. Notably, CLDN8 knockout significantly reduces Cl- permeability, highlighting its importance in the function of collecting ducts .

While CLDN8 cannot form tight junction strands independently, it can associate with other claudins to regulate tight junction structural and functional strand dynamics . A particularly important interaction occurs with CLDN4, as CLDN8 may coassemble with CLDN4 into tight junction strands containing anion-selective channels that convey paracellular chloride permeability in renal collecting ducts .

What sample types are suitable for CLDN8 antibody applications?

Based on validated research applications, CLDN8 antibodies have been successfully used with various sample types:

• Cell lines: HeLa and HEK293 whole cell lysates have been used for Western blot analysis, showing a band at approximately 25 kDa .

• Tissue samples: CLDN8 antibodies have been used for immunohistochemical (IHC) staining in kidney tissue samples, including clear cell renal cell carcinoma (ccRCC) and normal kidney tissues .

• Clinical specimens: In studies examining CLDN8 expression in ccRCC, tissue microarrays with 105 KIRC samples and 16 non-KIRC tissues have been successfully used for immunohistochemistry .

For optimal results, researchers should validate antibody performance with their specific samples of interest, as expression levels may vary significantly between tissues and disease states.

How can I validate the specificity of a CLDN8 antibody?

A multi-level validation approach is recommended:

• Positive and negative control tissues: Use tissues known to express high levels of CLDN8 (e.g., normal kidney tissue) and those with minimal expression as controls.

• Western blot analysis: Validate specificity by observing a band at the expected molecular weight (~25 kDa) in appropriate cell lines such as HeLa or HEK293 .

• Knockdown/knockout validation: Use siRNA knockdown or CRISPR knockout of CLDN8 in cell lines to confirm antibody specificity. The reduced signal in knockdown samples compared to controls provides strong evidence of specificity.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to samples; a significant reduction in signal indicates specificity for the target epitope.

• Correlation with mRNA expression: Compare protein detection with mRNA expression data from qPCR or RNA-seq to ensure concordance between protein and transcript levels .

What is the role of CLDN8 in renal cell carcinoma, and how can antibodies help elucidate its function?

CLDN8 is significantly downregulated in kidney renal clear cell carcinoma (KIRC/ccRCC) compared to normal kidney tissues . This downregulation has been consistently observed across multiple datasets comprising over 1,000 KIRC samples and 450 non-cancerous control samples . The differential expression of CLDN8 demonstrates remarkable diagnostic potential, with studies reporting an area under the curve (AUC) of approximately 1.00 (95% CI: 0.99-1.00) for distinguishing KIRC from non-KIRC tissues .

CLDN8 appears to function as a tumor suppressor in ccRCC. CRISPR knockout screen technology has revealed that knocking out the CLDN8 gene results in faster growth in 20 KIRC cell lines, suggesting CLDN8 plays an inhibitory role in KIRC cell proliferation . Additionally, functional studies with the 786-O ccRCC cell line have demonstrated that CLDN8 suppresses proliferation, migration, and invasion through the EMT and AKT pathways .

Researchers can use CLDN8 antibodies to:

• Assess CLDN8 protein levels in patient samples for potential prognostic value

• Study the molecular mechanisms through which CLDN8 exerts its tumor-suppressive effects

• Investigate the relationship between CLDN8 expression and response to therapy

• Examine co-localization with other tight junction proteins to understand structural changes in cancer cells

What methodological considerations are important for quantifying CLDN8 expression in tissue samples?

When quantifying CLDN8 expression in tissue samples, especially for prognostic or diagnostic purposes, several methodological considerations are critical:

• Standardized scoring system: The immunoreactive score (IRS) system (0-12 points) has been successfully used in CLDN8 studies. This combines staining intensity (graded 0-3: negative, weak, medium, and strong) with the proportion of positively stained cells (0: <10%, 1: 10-25%, 2: 26-50%, 3: 51-75%, and 4: 76-100%) .

• Multiple field assessment: Evaluate each sample in multiple visual fields (e.g., five different fields per sample) to account for heterogeneity, with the arithmetic average representing the final score .

• Independent pathologist validation: Have at least two pathologists independently evaluate staining results to ensure reliability and reduce subjective bias .

• Appropriate controls: Include both positive and negative controls in each batch of staining to ensure consistency across experiments.

• Digital image analysis: Consider using computational image analysis tools to obtain objective quantification, particularly for large-scale studies.

• Correlation with clinical data: Analyze CLDN8 expression in relation to clinical parameters such as survival time, tumor grade, and stage to assess prognostic value .

How can single-cell analysis techniques be applied to study CLDN8 expression heterogeneity?

Single-cell analysis provides valuable insights into CLDN8 expression patterns at the cellular level, particularly important in heterogeneous tissues like tumors. Based on research approaches:

• Single-cell RNA sequencing (scRNA-seq): Has been successfully applied to study CLDN8 expression in KIRC. For example, dataset GSE152938 was used to analyze CLDN8 expression at the single-cell level, confirming significant downregulation in KIRC single cells compared to normal cells (P < 0.0001) .

• Quality control parameters: When analyzing scRNA-seq data for CLDN8, researchers should apply appropriate quality filters (e.g., 200 < nFeature_RNA < 2,500 and mitochondrial proportion < 5%) to ensure reliable results .

• Clustering approach: Optimal clustering with resolution set to 0.8 and dims to 18, visualized using UMAP, has been effective for analyzing CLDN8 expression patterns .

• Correlation with cell types: Researchers should analyze CLDN8 expression across different cell populations within the tissue microenvironment to identify cell-type specific regulation.

• Integration with spatial information: Combining single-cell transcriptomics with spatial transcriptomics or multiplexed immunofluorescence can provide insights into the relationship between CLDN8 expression and tissue architecture.

• Functional validation: Following identification of CLDN8 expression patterns at the single-cell level, functional studies in relevant cell populations can clarify biological significance.

What is the optimal protocol for CLDN8 immunohistochemistry in tissue samples?

Based on published methodologies, the following protocol has been validated for CLDN8 immunohistochemistry:

• Tissue preparation: Use formalin-fixed, paraffin-embedded (FFPE) tissue sections (4-6 μm thickness).

• Antibody selection: Anti-CLDN8 antibody (e.g., ab211439 from Abcam) has been successfully used in IHC applications .

• Deparaffinization and rehydration: Follow standard protocols using xylene and decreasing concentrations of ethanol.

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0) at 95-100°C for 15-20 minutes.

• Blocking: Use 3% hydrogen peroxide to block endogenous peroxidase activity, followed by blocking with 5% normal goat serum.

• Primary antibody incubation: Dilute anti-CLDN8 antibody appropriately (typically 1:100 to 1:500 depending on the specific antibody) and incubate overnight at 4°C .

• Detection system: The horseradish peroxidase system has been successfully used for CLDN8 detection . After washing, incubate with HRP-conjugated secondary antibody (typically 1:200 dilution) for 1-2 hours at room temperature.

• Visualization: Develop with DAB (3,3'-diaminobenzidine) substrate, counterstain with hematoxylin, dehydrate, and mount.

• Evaluation: Assess staining using the immunoreactive score (IRS) system as described earlier, examining multiple fields per sample .

What are the recommended troubleshooting steps for weak or non-specific CLDN8 immunostaining?

When encountering challenges with CLDN8 immunostaining, consider these troubleshooting approaches:

For weak staining:

• Optimize antibody concentration: If signal is weak, try increasing antibody concentration incrementally.

• Improve antigen retrieval: Extend antigen retrieval time or try alternative methods (e.g., EDTA buffer pH 9.0 instead of citrate buffer).

• Increase incubation time: Extend primary antibody incubation (e.g., 48 hours at 4°C instead of overnight).

• Enhance detection: Use signal amplification systems like tyramide signal amplification (TSA).

• Check sample quality: Ensure tissues were properly fixed and processed; excessive fixation can mask epitopes.

For non-specific staining:

• Optimize blocking: Increase blocking time or concentration, or try alternative blocking agents.

• Reduce antibody concentration: Dilute primary antibody further if background is high.

• Additional blocking steps: Include avidin/biotin blocking if using biotinylated secondary antibodies.

• Increase washing: Extend washing steps between antibody incubations.

• Test alternative antibodies: Compare results with different anti-CLDN8 antibodies targeting distinct epitopes.

• Include appropriate controls: Include isotype controls and known positive/negative tissues.

What are the optimal protocols for detecting CLDN8 by Western blot?

Based on successful applications in published research, the following protocol is recommended for CLDN8 Western blot analysis:

• Protein extraction: Extract total proteins from cells using NP-40 lysis buffer. For tissue samples, consider using RIPA buffer with protease inhibitors .

• Protein quantification: Quantify proteins using the bicinchoninic acid (BCA) method to ensure equal loading .

• Sample preparation: Mix 20-30 μg of protein with loading buffer containing SDS and β-mercaptoethanol, then heat at 95°C for 5 minutes.

• Gel electrophoresis: Separate proteins on a 12-15% SDS-PAGE gel (CLDN8 has a molecular weight of approximately 25 kDa) .

• Transfer: Transfer proteins to a polyvinylidene fluoride (PVDF) membrane at 100V for 1-2 hours in cold transfer buffer .

• Blocking: Block membrane with 5% non-fat milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody: Incubate with anti-CLDN8 antibody at an optimal dilution (typically 1:1000 to 1:2000) overnight at 4°C .

• Secondary antibody: After washing, incubate with peroxidase-coupled anti-rabbit IgG (1:1000 to 1:5000) at room temperature for 1-2 hours .

• Detection: Visualize bands using enhanced chemiluminescence (ECL) detection systems .

• Quantification: Use β-actin (1:1000) as a loading control for normalization when quantifying CLDN8 expression levels .

How can CLDN8 expression be studied in the context of tight junction formation?

To study CLDN8 in the context of tight junction formation, researchers should consider these methodological approaches:

• Co-immunoprecipitation studies: To investigate interactions between CLDN8 and other tight junction proteins, particularly CLDN4, with which it has been shown to interact functionally .

• Immunofluorescence co-localization: Use double or triple immunofluorescence staining to visualize the co-localization of CLDN8 with other tight junction proteins like CLDN4, occludin, or ZO-1.

• Proximity ligation assay (PLA): Apply this technique to detect and visualize protein-protein interactions between CLDN8 and other tight junction components with single-molecule resolution.

• FRET (Förster Resonance Energy Transfer): Use FRET to study the dynamic interactions between CLDN8 and other tight junction proteins in living cells.

• Barrier function assays: Following manipulation of CLDN8 expression, measure transepithelial electrical resistance (TEER) and paracellular permeability to assess functional effects on tight junction integrity.

• Freeze-fracture electron microscopy: Visualize the incorporation of CLDN8 into tight junction strands and how this affects strand morphology.

What are the best approaches for studying CLDN8 function using genetic manipulation techniques?

Several genetic manipulation approaches have been successfully applied to study CLDN8 function:

• CRISPR-Cas9 knockout: CRISPR knockout screen technology has been effectively used to evaluate the effect of CLDN8 on cell growth. Studies have shown that knocking out the CLDN8 gene resulted in faster growth in multiple KIRC cell lines, indicating its tumor-suppressive role .

• Overexpression studies: For overexpression, PCR amplification of CLDN8 with appropriate enzyme sites (XhoI and BamHI) and cloning into expression vectors (e.g., pLVX) has been successful. Primers used in published research include:

  • Forward CLDN8 primer: 5ʹ-CCGCTCGAGGCCACCATGGCAACCCATGCCTTAG-3ʹ

  • Reverse CLDN8 primer: 5ʹ-CGGGATCCCTACACATACTGACTTCTGGAGTAGAC-3ʹ

• Lentiviral transduction: For stable expression, packaging CLDN8 constructs into lentivirus and transducing target cells (e.g., 786-O cells at MOI = 50) followed by antibiotic selection (e.g., blasticidin at 5 μg/mL) has proven effective .

• Functional validation assays: After genetic manipulation, functional changes can be assessed using:

  • Proliferation assays (e.g., MTT/CCK-8)

  • Migration assays (e.g., wound healing assay with observations at 0, 6, and 24 hours)

  • Invasion assays (e.g., Transwell)

  • Analysis of downstream signaling pathways (e.g., EMT and AKT pathways)

How can bioinformatic analyses be integrated with experimental studies of CLDN8?

Integrating bioinformatic analyses with experimental studies provides a comprehensive understanding of CLDN8 function:

• Differential expression analysis: Multiple datasets (e.g., TCGA, GEO, ICGC) can be analyzed to establish CLDN8 expression patterns across tissues and disease states. Meta-analysis approaches combining these datasets provide robust evidence of expression changes .

• Survival analysis: Kaplan-Meier curves can assess the relationship between CLDN8 expression levels and patient outcomes. Lower CLDN8 expression in KIRC has been associated with shorter survival time (hazard ratio = 1.69, 95% CI: 1.2-2.4) .

• Gene set enrichment analysis (GSEA): This approach identifies biological pathways associated with CLDN8 expression. Samples can be classified into high and low groups based on CLDN8 expression, and gene set permutations (1000 times) can identify significantly enriched gene sets (FDR q-value <0.05) .

• Single-sample gene set enrichment analysis (ssGSEA): This method can evaluate the immune microenvironment in relation to CLDN8 expression, predicting immune cell concentrations and analyzing correlations between CLDN8 expression and immune cell infiltration .

• Experimental validation: Key findings from bioinformatic analyses should be validated experimentally. For example, pathways identified through GSEA can be investigated using Western blot analysis of pathway components or pharmacological inhibitors targeting these pathways.